Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing.
Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
“At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer’s is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.”
Key Scientific Sessions and Presentations:
- Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month Analysis
Wednesday, July 30, 8:00–8:45 AM ET - Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer’s Disease
Wednesday, July 30, 9:00–10:30 AM ET - Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery
Sunday, July 27, 8:00–8:45 AM ET - Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway Learnings
Sunday, July 27, 9:00–10:30 AM ET - Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results
Sunday, July 27, 4:14–5:45 PM ET - Innovations in Tau Therapies and Biomarkers for Alzheimer’s Disease: Bridging Research and Clinical Practice
Wednesday, July 30, 2:00–3:30 PM ET - Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer’s Disease
Monday, July 28, 7:30 AM–4:15 PM ET
Educational Program on Tau in Alzheimer’s Disease
At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer’s disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on KnowTau.com, building on the resources already available.
